Found 72 articles
QurAlis to Present Data That Show TDP-43 Pathology Drives Loss of Synaptic UNC13A Function in Neurodegenerative Diseases Including ALS and Frontotemporal Dementia
QurAlis Corporation today announced it will present preclinical data showing that TDP-43 (TAR DNA-binding protein 43) pathology drives loss of synaptic UNC13A function in neurodegenerative diseases including ALS and FTD.
QurAlis Corporation today announced that Kasper Roet , Ph.D., chief executive officer and founder, will present at the Piper Sandler 35th Annual Healthcare Conference being held November 28-30, 2023 in New York, NY.
QurAlis to Present Data Showing Link Between TDP-43 Pathology and Role of UNC13A in Neuronal Biology Related to ALS and Other Neurodegenerative Diseases
QurAlis today announced it will present preclinical data showing that TDP-43 (TAR DNA-binding protein 43) pathology drives loss of synaptic UNC13A function in neurodegenerative diseases including ALS and frontotemporal dementia (FTD).
QurAlis Receives Clinical Trial Authorisation (CTA) in the U.K. for QRL-201, a First-in-Class STATHMIN-2 Precision Therapy for ALS
QurAlis Corporation today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom (U.K.) has completed review of the Clinical Trial Application (CTA) and has issued a notice of acceptance for QRL-201 for the potential treatment of ALS.
QurAlis and Unlearn Announce Collaboration to Accelerate and Optimize ALS Clinical Trials With Generative Artificial Intelligence Technologies
QurAlis Corporation and Unlearn today announced they have entered into a collaboration to accelerate and optimize QurAlis' clinical program in ALS with Unlearn's advanced generative artificial intelligence (AI) technology.
The majority of ALS patients are excluded from clinical trials. Experts say using biomarkers and stratifying trial populations can expand eligibility and provide additional scientific insights.
QurAlis Corporation announced it will present new preclinical data showing the potential of the company's antisense oligonucleotides generated from its proprietary FlexASO™ Splice Modulator Platform.
QurAlis Receives Clinical Trial Authorisation (CTA) in European Union (EU) for QRL-201, a First-in-Class STATHMIN-2 Precision Therapy for ALS
QurAlis Corporation, a clinical-stage biotechnology company developing breakthrough precision medicines for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases with genetically validated targets, today announced that the European review has been completed for the Clinical Trial Regulation (CTR) and each participating country has issued a notice of acceptance for QRL-201 for the potential treatment of ALS.
QurAlis Corporation today announced that Kasper Roet , Ph.D., CEO and co-founder, will participate in the following conferences.
Wave will discontinue development of WVE-004 in C9-associated ALS and frontotemporal dementia after the therapy failed to show any clinical benefit in a mid-stage trial.
For people with, or at risk for, SOD1-ALS, the FDA's approval of Qalsody is an important step toward advancing gene-specific research for this uniformly fatal disease.
Phase IIa data showed AI Therapeutics' ALS candidate increased expression of a target engagement biomarker and led to a 73% reduction in a toxic protein aggregate.
QurAlis Announces First Patient Dosed With QRL-201, a First-in-Class STATHMIN-2 Precision Therapy for ALS
QurAlis Corporation today announced that the first patient has been dosed in its Phase 1 clinical trial of QRL-201 for the treatment of ALS (ANQUR).
Recently, 6 of Viva's portfolio companies have achieved significant results and progress: Mediar and QurAlis have successfully completed financing, while AmacaThera, AceLink, Basking, and TechnoDerma have made smooth progress in their R&D pipelines.
NRG Therapeutics, Ltd., an innovative neuroscience company targeting mitochondrial dysfunction, is pleased to announce the formation of its scientific advisory board, to support and steer its R&D programmes to develop novel small molecule therapies for the treatment of neurodegenerative disorders.
Biomarkers as a surrogate endpoint in ALS will go on trial on March 22 as Biogen and Ionis’s tofersen faces the FDA’s Peripheral and Central Nervous System Drugs Advisory Committee.
QurAlis Reveals Newest Program Targeting UNC13A RNA Mis-splicing Incorporating its FlexASO™ Platform
QurAlis Corporation announced the launch of its newest program that targets UNC13A mis-splicing, a critical genetic alteration in neurodegenerative diseases like ALS and frontotemporal dementia.
QurAlis has taken a biomarker-driven approach to treating ALS all the way to another bank deposit, closing an oversubscribed $88 million Series B round Thursday.
QurAlis Closes $88 Million Series B Financing to Advance Precision Medicines for Neurodegenerative Diseases
QurAlis Corporation announced it has closed an oversubscribed $88 million Series B financing, bringing the total funds raised to $143.5 million.
The FDA's Peripheral and Central Nervous System Drugs advisory committee will discuss the merits of Biogen and Ionis's ALS candidate tofersen on March 22nd.